Literature DB >> 9870483

A controlled trial of two bicarbonate-containing dialysis fluids for CAPD--final report.

G A Coles1, D J O'Donoghue, N Pritchard, C S Ogg, F M Jani, R Gokal, G C Cancarini, R Maiorca, A Tranaeus, C De Vos, A Hopwood, D Faict.   

Abstract

BACKGROUND: The combination of a low pH and a high concentration of lactate which is present in most dialysis fluids is found to be cytotoxic in vitro. For these reasons it would seem logical to use a bicarbonate-containing solution and thus automatically provide a solution with a neutral pH.
METHODS: A parallel, randomized, open-label, prospective 2-month trial with an optional 4 month extension was undertaken to compare two novel bicarbonate-based solutions; one containing 38 mmol/l of bicarbonate (B), and one containing a mixture of 25 mmol/l bicarbonate and 15 mmol/l of lactate (B/L), with a control solution (C) containing 40 mmol/l lactate.
RESULTS: Three groups of 19 (C), 20 (B), and 20 (B/L) patients were recruited and data from approximately 55 patient months were accumulated in each group. The data show that both bicarbonate-based solutions maintain acid-base levels within the normal range, that there were no changes in any of the other blood biochemistry parameters measured in the peritoneal equilibration test or with regard to adequacy of dialysis, and that furthermore, both solutions were well tolerated.
CONCLUSIONS: This study showed that either the bicarbonate or bicarbonate/lactate solutions could be utilized efficaciously in patients undergoing CAPD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870483     DOI: 10.1093/ndt/13.12.3165

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

Review 1.  Correction of chronic metabolic acidosis for chronic kidney disease patients.

Authors:  P Roderick; N S Willis; S Blakeley; C Jones; C Tomson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  The Association Between Glucose Exposure and the Risk of Peritonitis in Peritoneal Dialysis Patients.

Authors:  Anouk T N van Diepen; Sadie van Esch; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2016-04-04       Impact factor: 1.756

3.  Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kym M Bannister; Philip A Clayton; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

4.  Strategies for preserving residual renal function in peritoneal dialysis patients.

Authors:  Arkom Nongnuch; Montira Assanatham; Kwanpeemai Panorchan; Andrew Davenport
Journal:  Clin Kidney J       Date:  2015-01-13

5.  A new peritoneal dialysis fluid for Japanese patients: a randomized non-inferiority clinical trial of safety and efficacy.

Authors:  Masaaki Nakayama; Yoshindo Kawaguchi; Takashi Akiba; Masao Kim; Hidemune Naito; Shigeko Hara; Teruhiko Maeba; Noriaki Yorioka; James A Sloand; Mark R Marshall
Journal:  Clin Exp Nephrol       Date:  2016-10-25       Impact factor: 2.801

6.  Biocompatible peritoneal dialysis fluids: clinical outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Kathryn Wiggins; David W Johnson
Journal:  Int J Nephrol       Date:  2012-11-28

7.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26

Review 8.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.